trending Market Intelligence /marketintelligence/en/news-insights/trending/IL5ScXdnlU-QCaY5ofrgpw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Osmotica Pharmaceuticals adds board member

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Osmotica Pharmaceuticals adds board member

Osmotica Pharmaceuticals PLC appointed Gregory Cowan to its board of directors and audit committee, effective Jan. 2, 2019.

Cowan previously served as executive vice president and CFO of Avantor Inc.

Bridgewater, N.J.-based Osmoticsa develops specialty products for underserved patient populations. Its products include M-72 for attention deficit hyperactivity disorder and Osmolex ER for Parkinson's and drug-induced extrapyramidal reactions in adults.